National Sleeping Sickness Control Program, Uganda Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2001
NCT00330148
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

eflornithine (ornidyl) (1 trial)

melarsoprol (1 trial)

nifurtimox (Lampit) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3